This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AngioDynamics Stock Up on Q3 Earnings Beat, Gross Margin Expands
by Zacks Equity Research
ANGO reports solid fiscal third-quarter earnings with continued strength in its Med Tech segment. The expansion of gross margin bodes well.
ALC Stock May Rise With the Introduction of PanOptix Pro in US
by Zacks Equity Research
Alcon introduces Clareon PanOptix Pro IOL to select practices across the United States, with commercial availability expected in May.
AVNS Stock Gains Following Direct Sales Deal for MIC-KEY in the UK
by Zacks Equity Research
Avanos takes direct control of MIC-KEY sales in the UK, enhancing market presence, customer engagement and service efficiency, starting July 2025.
MIST Stock Falls 66% Following Complete Response Letter for Cardamyst
by Zacks Equity Research
Milestone Pharmaceuticals faces an FDA setback for its PSVT nasal spray. The company coordinates with regulatory authorities to resolve CRL issues.
3 Stocks to Buy for "Liberation" From Trump Tariffs & Recession Woes
by Urmimala Biswas
In 2025, companies like MASI, BSX and HIMS are expected to overcome challenges and sustain strong growth and market leadership.
Masimo (MASI) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Masimo (MASI) is well positioned to outperform the market, as it exhibits above-average growth in financials.
VEEV Stock Slips Despite New Research Site Clinical Trial System
by Zacks Equity Research
Veeva introduces a Research Site Clinical Trial Management System to streamline trial operations, enhance collaboration, and accelerate clinical research efficiency.
ALGN Stock Gains From the Invisalign System With Mandibular Advancement
by Zacks Equity Research
Align Technology's Invisalign System, featuring mandibular advancement with occlusal blocks, is now commercially available for Class II malocclusion in the growing number of patients.
Here's Why You Should Retain Revvity Stock in Your Portfolio for Now
by Zacks Equity Research
RVTY's strong product portfolio raises optimism about the stock.
GEHC Stock May Rise as Revolution Vibe CT Enhances Imaging Tech
by Zacks Equity Research
GE HealthCare introduces Revolution Vibe CT, a cutting-edge imaging system designed to enhance diagnostic precision, improve workflow efficiency, and expand accessibility.
ABT Stock Gains Following the Positive TRILUMINATE Trial Results
by Zacks Equity Research
Abbott presents positive TRILUMINATE Pivotal trial data, which demonstrates TriClip system's safety and effectiveness at the ACC.25.
Here's Why You Should Retain Merit Medical Stock in Your Portfolio Now
by Zacks Equity Research
Merit Medical's strong product portfolio raises optimism about the stock.
Here's Why You Should Retain OPKO Health Stock in Your Portfolio
by Zacks Equity Research
OPK's growth is fueled by Rayaldee's success and promising pipeline progress. However, margin pressure and overdependence on its lead product are concerning.
IceCure Medical Stock Dips Despite Positive ICESECRET Study Results
by Zacks Equity Research
ICCM reports strong kidney cancer cryoablation study results, showcasing 88.7% recurrence-free rates and reinforcing its position in cryoablation technology.
International Expansion, Product Launches Support BSX Stock
by Zacks Equity Research
Boston Scientific continues to successfully expand its operations across various geographies outside the United States.
Masimo (MASI) Down 12.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Intelligent Bio Solutions Stock Drops Despite Key U.S. Patent Win
by Zacks Equity Research
INBS secures a key U.S. patent, strengthening its IP protection and paving the way for 2025 market entry with innovative biometric technology.
Here's Why You Should Hold AVTR Stock in Your Portfolio for Now
by Zacks Equity Research
Avantor is set for growth with a strong portfolio and solid fourth quarter results, but challenges like customer losses and forex volatility pose potential risks.
Prestige Consumer Gains 17.1% in a Year: What's Driving the Stock?
by Zacks Equity Research
PBH's shares rise on the back of its portfolio of consumer brands and focus on core strategies to achieve long-term success.
CAH Stock Rises More Than 13% YTD: Should You Buy, Hold or Sell?
by Zacks Equity Research
Cardinal Health's recent acquisitions and GMPD recovery look promising. However, the loss of the Optum Rx contract and margin pressure are likely to hurt short-term prospects.
Merit Medical Stock May Rise as WRAPSODY CIE Shows Strong Results
by Zacks Equity Research
MMSI unveils 12-month efficacy data for WRAPSODY CIE, highlighting its advanced technology in vascular access maintenance and potential to improve patient outcomes.
Alcon Stock Might Rise as Clareon Vivity IOL Secures CE Mark Approval
by Zacks Equity Research
ALC secures CE Mark for Clareon Vivity IOL, bringing advanced presbyopia-correcting lens technology to Europe, enhancing visual outcomes with cutting-edge innovation.
ALC Stock Rises Following the Merger Agreement With LENSAR
by Zacks Equity Research
Alcon enters into a definitive merger agreement to acquire LENSAR's ALLY Robotic Cataract Laser Treatment System, proprietary Streamline software technology and LENSAR legacy laser system.
BDX Shares May Climb as GalaFLEX LITE Trial Hits Key Milestone
by Zacks Equity Research
BD advances its clinical trial for the bioabsorbable GalaFLEX LITE scaffold, aiming to improve outcomes in breast implant revision surgeries and patient recovery.
Here's Why You Should Hold GEHC Stock in Your Portfolio for Now
by Zacks Equity Research
GE HealthCare's continued focus on innovations, acquisitions and partnerships raises optimism about the stock.